ROCKET PHARMACEUTICALS, INC. - 8-K Filing

Rocket Pharmaceuticals reports positive safety data for RP-A501 in initial three patients under modified Phase 2 trial protocol (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $RCKT

Read the full article at SEC EDGAR

More Regulatory news